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Pharmacogenetic testing is becoming more common;
however, very few quality control and other reference
materials that cover alleles commonly included in such
assays are currently available. To address these needs,
the Centers for Disease Control and Prevention’s Ge-
netic Testing Reference Material Coordination Program,
in collaboration with members of the pharmacogenetic
testing community and the Coriell Cell Repositories,
have characterized a panel of 107 genomic DNA refer-
ence materials for five loci (CYP2D6, CYP2C19,
CYP2C9, VKORC1, and UGT1A1) that are commonly
included in pharmacogenetic testing panels and profi-
ciency testing surveys. Genomic DNA from publicly
available cell lines was sent to volunteer laboratories for
genotyping. Each sample was tested in three to six labo-
ratories using a variety of commercially available or labo-
ratory-developed platforms. The results were consistent
among laboratories, with differences in allele assignments
largely related to the manufacturer’s assay design and vari-
able nomenclature, especially for CYP2D6. The alleles in-
cluded in the assay platforms varied, but most were iden-
tified in the set of 107 DNA samples. Nine additional
pharmacogenetic loci (CYP4F2, EPHX1, ABCB1, HLAB,
KIF6, CYP3A4, CYP3A5, TPMT, and DPD) were also
tested. These samples are publicly available from Coriell
and will be useful for quality assurance, proficiency
testing, test development, and research. (J Mol Diagn
2010, 12:835–846; DOI: 10.2353/jmoldx.2010.100090)
Many laboratories are testing for pharmacogenetic (PGx)
markers, common genetic variants that are usually con-
sidered only when a patient is likely to be exposed to a
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particular pharmaceutical. There are, however, very few
publicly available characterized quality control and other
reference materials (RMs) for PGx markers to assure the
quality of testing. These materials are necessary for test
development, test validation, quality control, and profi-
ciency testing. Moreover, the available materials do not
include many of the alleles tested in laboratory PGx as-
says. Publicly available cell lines may be used as RMs,
but few have been characterized for multiple PGx loci
and multiple alleles.
The clinical laboratory testing community has expressed
a desire for RMs that are characterized for multiple PGx loci.
To address these needs, the Centers for Disease Control
and Prevention (CDC)-based Genetic Testing Reference
Material Coordination Program (GeT-RM, http://wwwn.cdc.
gov/dls/genetics/rmmaterials/default.aspx, last accessed on
June 16, 2010) in collaboration with the Association for
Molecular Pathology, members of the pharmacogenetic
testing community and the Coriell Cell Repositories (Cam-
den, NJ), have characterized a panel of 107 genomic DNA
RMs for five loci (CYP2D6, CYP2C19, CYP2C9, VKORC1,
and UGT1A1) commonly included in PGx testing panels
and proficiency testing surveys. These genomic DNA sam-
ples are publicly available from Coriell and can be used for
quality assurance, assay development, and validation as
well as for proficiency testing.
Pharmacogenetic testing encompasses molecular
testing for common genetic variants associated with hu-
man variability in drug response. There are a consider-
able number of polymorphisms in many of the human
genes associated with pharmacokinetics or pharmaco-
dynamics of exogenous drugs. Pharmacogenetic se-
quence variants are designated by a nomenclature of
*(star) alleles, where *1 is designated as normal (com-
monly referred to as wild-type or fully functional) and
subsequent variant alleles are numbered in the order that
they are identified and characterized. Within each ‘*’
allele designation, additional variations that are linked
in cis with the defining single nucleotide polymorphism
(SNP) create subfamilies that are designated alphabet-
ically in the order that they are described (eg, *2A, *2B,
*2C). Unlike many heritable disease mutations, each
PGx allele may include several SNPs, rather than a
single site mutation. The PGx nomenclature adds to the
analytic and reporting complexity, especially when try-
ing to compare various assay platforms. PGx gene
variants typically characterize drug metabolizing en-
zymes, drug transporters, drug receptors, or targets of
drug action.
The human liver is the primary site responsible for
processing and transforming a variety of toxins and other
compounds, including pharmaceuticals, into active or
inactive metabolites. This activity is mediated by dozens
of metabolic enzymes with a wide range of biochemical
activities. Cytochrome P450 (CYP450) is a superfamily of
liver enzymes that catalyzes the conversion of sub-
stances that are excreted from the body. The CYP450s
metabolize substrates through a variety of reactions (in-
cluding epoxification, N-dealkylation, O-dealkylation, S-
oxidation and hydroxylation). The substrates include not
only drugs and hormones but also food and dietary com-
ponents, occupational pollutants, and industrial chemi-
cals. More than half of all drugs are primarily metabolized
by the CYP450 enzymes.1 Fifty-seven cytochrome P450
enzymes have been identified in humans, 15 of which are
involved in metabolism of xenobiotic compounds, includ-
ing pharmaceuticals.1 The activity of each enzyme en-
coded by the combination of cytochrome P450 *alleles is
categorized as one of four possible phenotypes: exten-
sive (normal) metabolizer, intermediate metabolizer, poor
metabolizer, and ultra-rapid metabolizer. There is some
variability in the phenotypes conferred by each genetic
variant that depend on the target substrate.
CYP2D6 is one enzyme in the CYP450 superfamily esti-
mated to metabolize approximately 25% of all clinically
used drugs.2 Some pharmaceuticals metabolized by
CYP2D6 include the following: cancer drugs such as ta-
moxifen, antidepressants such as fluoxetine and amitripty-
line, and narcotic analgesics such as codeine. TheCYP2D6
gene, located on chromosome 22, is highly polymorphic.
Currently there are more than 75 alleles described for
CYP2D6 (HumanCytochrome P450 [CYP] Allele Nomencla-
ture Committee http://www.cypalleles.ki.se/cyp2d6.htm, last
accessed on February 11, 2010). Each allele has varying
frequencies based on the ethnic background of the patient
population.3,4
CYP2C19, another member of the cytochrome P450 fam-
ily, is important for the metabolism of a number of hormones
and prescription drugs including omeprazole, clomipra-
mine, and clopidogrel. A variety of alleles, including the
common nonfunctional (poor metabolizing) *2 and *3 vari-
ants, as well as an ultra-rapid metabolizing *17 variant, exist
for this enzyme (Human Cytochrome P450 [CYP] Allele
Nomenclature Committee http://www.cypalleles.ki.se/cyp2c19.
htm, last accessed on December 15, 2009). The frequency
of these alleles varies among different ethnic populations.3
The FDA changed the boxed warning label on Plavix (clo-
pidogrel), to recommend CYP2C19 testing to identify poor
metabolizers (http://www.fda.gov/Drugs/DrugSafety/
PostmarketDrugSafetyInformationforPatientsandProviders/
ucm203888.htm, last accessed on June 15, 2010).
Inconsistency in response to the anticoagulant warfa-
rin is affected by genetic variability in the enzymes
CYP2C9, which metabolizes warfarin and Vitamin K ep-
oxide reductase complex subunit 1 (VKORC1), the target
of warfarin action. Warfarin has a narrow therapeutic
index, variable dosing requirements, and necessitates
frequent monitoring of prothrombin time to achieve safe
and effective reduction of thrombotic risk. Testing for
genetic differences that contribute to variable warfarin
response can aid in the clinical management of patients
receiving warfarin therapy, although this has been con-
troversial.5 CYP2C9 and VKORC1 genotyping can be
used to guide dosing and may help minimize adverse
drug reactions such as bleeding from excess administra-
tion of anticoagulants and thrombosis caused by under-
dosing.6 Commonly tested alleles include CYP2C9 *2
and *3 (slow metabolizing alleles) (Human Cytochrome
P450 [CYP] Allele Nomenclature Committee http://www.
cypalleles.ki.se/cyp2c9.htm, last accessed on February
11, 2010), and VKORC1 c.1639GA, all of which are
associated with increased sensitivity to warfarin.7
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UGT1A1 encodes UDP-glucuronosyltransferase, an en-
zyme responsible for the inactivation by glucuronidation of
the active metabolite of irinotecan (SN38), a drug frequently
used to treat patients with metastatic colorectal cancer. The
FDA labeling of irinotecan suggests UGT1A1 genotyping
before treatment of the patient (http://www.fda.gov/Safety/
MedWatch/SafetyInformation/ucm215480.htm, last ac-
cessed on June 15, 2010). The most common UGT1A1
allele, *1, has 6 TA repeats in the TATA box of the promoter.
In addition, there are three UGT1A1 variant alleles that differ
in the number of TA repeats (*28, *36 and *37 with 7, 5, and
8 TA repeats, respectively; Canada Research Chair in Phar-
macogenetics http://www.pharmacogenomics.pha.ulaval.
ca/webdav/site/pharmacogenomics/shared/Nomenclature/
UGT1A/UGT1A1.htm, last accessed on March 10, 2010).
These variants affect the expression and activity levels of
the enzyme, and their allele frequency varies among differ-
ent ethnic groups. Individuals homozygous for the *28 allele
(10% of the U.S. population) metabolize irinotecan more
slowly and are at increased risk for toxicity including high-
grade neutropenia and/or diarrhea during irinotecan ther-
apy (Pharmacogenomics Knowledge Base http://www.
pharmgkb.org/do/serve?objIdPA420&objClsGene, last
accessed on January 18, 2010).
This study describes the collaborative characterization
of 107 publicly available genomic DNA reference mate-
rials for pharmacogenetic testing by the GeT-RM pro-
gram and the genetic testing community.
Materials and Methods
Cell Line and Laboratory Selection
One hundred seven cell lines were selected from the
National Institute of General Medical Sciences (NIGMS)
Repository at the Coriell Cell Repositories for this study
based on partial genotypic characterization, availability
of DNA, and the varied ethnicities of the donors. All
Coriell DNA and cell line materials are stripped of iden-
tifiers on submission and are assigned a Coriell cell line
number. Therefore these samples are HIPPA compliant.
Volunteer laboratories were selected based on assay
platform as well as number of samples they were able to
test. Both clinical genetic and commercial assay manu-
facturing laboratories participated in the study. DNA was
prepared by Coriell, and sample sets were sent to the
volunteer laboratories for genotyping. Participants used a
variety of commercially available tests, both FDA-cleared
and non–FDA-cleared, as well as laboratory developed
tests (LDTs). Nearly all commercially available platforms
were represented in this study (Table 1). The specific
alleles detected by each assay varied (Table 1). Re-
agents for some of the assays were generously donated
by Applied Biosystems Inc, AutoGenomics, Inc., Hologic,
Inc. (formerly Third Wave Technologies), Luminex Molec-
ular Diagnostics, Osmetech Molecular Diagnostics, and
Roche Diagnostics.
Table 1. Loci and Alleles Detected by Each Assay†











*2–*11, *15, *17, *19, *20,
*29, *35, *36, *40, *41,
*1XN, *2XN, *4XN, *10XN,
*17XN, *35XN, *41XN
(sets 1, 2, 3)‡
*2–*3 (sets 1, 2, 3) *2–*6, *11 (sets 1, 2, 3) 3673, 5808, 6009, 6484,
6853, 7566, 8773, 9041
(sets 1, 2, 3)






Idaho Tech (LDT with
ASRs)
Idaho Tech (LDT with
ASR)
PCR/CE (LDT)
*28, *36, *37 (set 3)
*2–*10, 12, *14, *17, *29,
*41, *XN (sets 1, 2, 3)
*2–*10, *17 (sets 1,
2, 3)
*2, *3 (sets 1, 2, 3) 3673 (sets 1, 2, 3)
Luminex (IUO) RFLP (LDT) TaqMan (LDT) Luminex (LDT) PCR/CE (LDT)
*2–*12, *14, *15, *17, 41,
*1XN, *2XN, *4XN,
*10XN, *17XN, *41XN
(sets 1, 2, 3)
*2, *3 (set 1) *2, *3, *5, *6, *8, *9, *11,
*12 (set 1)
3673 (set 1, 2) *28,*36, *37 (set 2)
ParagonDx (RUO) TaqMan (LDT) Luminex (LDT) SNaPShot (LDT) PCR/CE (LDT)
*2–*7, *10, *17, *29, *35,
*41, *1XN, *2XN, *4XN
(set 1)
*2–*9, *12 (set 1) *2, *3 (sets 1, 2) 3673 (sets 1, 2, 3) *28, *36, *37 (set 1)
LDT SNaPShot (LDT)
*2-*8, *10, *17, *2XN
(set 1)
Luminex (IUO)
*2–*8 (sets 1, 2, 3)
SNaPShot (LDT)
*2, *3, *5, *6 (sets 1, 2, 3)
Osmetech eSensor
(FDA-cleared)
3673 (sets 1, 2, 3)
Hologic, Inc. Invader
(FDA-cleared)
*28, *36, *37 (sets
1, 2, 3)
Osmetech eSensor (IUO)
*2, *3, *5, *6, *11, *14–16
(sets 1, 2, 3)
† All assays assume *1 if no mutations are detected.
‡ Indicates sample set(s) tested.
LDT, laboratory-developed test; RUO, research use only; IUO, investigational use only; ASR, analyte-specific reagents; PCR/CE, polymerase chain
reaction/capillary electrophoresis; RFLP, restriction fragment length polymorphism.
Bold type indicates name of Assay.
Pharmacogenetic Reference Materials 837
JMD November 2010, Vol. 12, No. 6
DNA Preparation
Approximately 2 mg of DNA was prepared from each of the
selected cell lines by the Coriell Cell Repositories using
Gentra/Qiagen Autopure (Valencia, CA) per manufacturer’s
instructions or previously described methods.8
Assays Used in the Characterization Study
CYP2D6 Assays
AutoGenomics INFINITI platform. The AutoGenomics
INFINITI 2D6 Mutation Detection Kit (AutoGenomics, Inc.,
Carlsbad, CA) simultaneously screens for 15 variants.
Briefly, extracted genomic DNA was amplified by PCR,
and alleles were distinguished using allele-specific
primer extension (ASPE). Extension of primers resulted in
incorporation of fluorescent CY5-dCTP. Extended prim-
ers were hybridized to complementary capture probes
immobilized on the BioFilmChip and fluorescence was
quantitated after scanning of the microarray using an
integrated optics unit. Genotypes were assigned auto-
matically by the proprietary software.9
Luminex xTag V2 platform. The Luminex xTag 2D6 Muta-
tion Detection Kit (Luminex Molecular Diagnostics, Aus-
tin, TX) simultaneously screens for 15 variants. Briefly,
genomic DNA was amplified in two PCR reactions, and
alleles were discriminated using ASPE and hybridization
to a universal microsphere array. Genotypes were de-
tected on a Luminex 100 IS System and assigned using
the proprietary TDAS software.10
ParagonDx. The ParagonDx 2D6 Real-time PCR reagents
(ParagonDx, LLC, Morrisville, NC) simultaneously screen
for nine alleles. Briefly, genomic DNA was amplified and
singleplex alleles were discriminated using the Strat-
agene Mx3005P QPCR System platform. Genotypes
were determined through end point fluorescence scatter
plot analysis. CYP2D6 *2A and *35 allelic genotypes were
determined by cycle sequencing using BigDye Termina-
tor Version 1.1 and the 3130xl Genetic Analyzer (Applied
Biosystems, Inc., Foster City, CA).11
Roche Amplichip platform. The Roche Amplichip P450
FDA-cleared Kit (Roche Diagnostics, Indianapolis , IN)
simultaneously screens for 27 alleles in the CYP2D6
gene. Genomic DNA was amplified in two multiplex PCR
reactions. After fragmentation and labeling, the PCR
products were denatured and hybridized to a microarray.
The signal was detected on an Affymetrix GeneChip
Scanner 3000Dx (Affymetrix, Santa Clara, CA) and alleles
assigned by AmpliChip CYP450_US Data Analysis
Software.12
The Applied Biosystems SNapShoT platform simulta-
neously screens for nine variants. Briefly, genomic DNA
is amplified and extension primers of varying lengths are
annealed to the amplicons. Each extension primer is
specific for a single site and ends one base upstream
from the mutation site. The primer extension reaction is
performed using fluorescently-labeled dideoxynucleoti-
des and the products are size-fractionated by capillary
electrophoresis. Automated allele calling is accom-
plished using Genotyper software and associated mac-
ros (Applied Biosystems, Inc., Foster City, CA).13
CYP2C19 Assays
AutoGenomics INFINITI platform. The AutoGenomics
INFINITI 2C19 Assay (AutoGenomics, Inc., Carlsbad,
CA) simultaneously screens for 10 variants. The proce-
dure was as described above for CYP2D6 using
CYP2C19 allele-specific PCR and detection primers and
assay-specific microarrays.14
Luminex xTag V2 platform. The Luminex xTag 2C19 Mu-
tation Detection Kit (Luminex Molecular Diagnostics, Aus-
tin, TX) simultaneously screens for seven variants. The
procedure was as described above for CYP2D6.
Roche Amplichip platform. The Roche Amplichip P450
FDA-cleared Kit (Roche Diagnostics, Indianapolis , IN)
simultaneously screens for two alleles in the CYP2C19
gene. See assay description above.
Laboratory-developed test using restriction fragment length
polymorphism (RFLP). This proprietary method for the de-
tection of two variants includes the amplification of
genomic DNA followed by restriction enzyme analysis.
The restriction products are size-fractionated by agarose
gel electrophoresis.
Laboratory-developed test for Taqman platform. Speci-
mens were analyzed using the Applied Biosystems Taq-
man Drug Metabolism Genotyping Assays (Applied Bio-
systems, Inc., Foster City CA) for the detection of nine
variants. This proprietary method includes the amplifica-
tion of genomic DNA followed by dual-labeled oligonu-
cleotides that hybridize to a specific target sequence.
Hydrolysis by the 53 exonuclease activity of Taq poly-
merase releases the fluorescent reporter signal, permit-
ting quantitative measurement of the accumulation of the
PCR product via the fluorophore signal.15 Manual allele
calling is accomplished using ABI 7900HT version 2.3
Sequence Detection Systems (SDS) software.
CYP2C9, VKORC1 assays
AutoGenomics INFINITI platform. The AutoGenomics
INFINITI CYP450 2C9-VKORC1 Assay (AutoGenomics,
Inc., Carlsbad, CA) simultaneously screens for six vari-
ants in CYP2C9 and eight variants in VKORC1. The pro-
cedure was as described above for CYP2D6 using
CYP2C9 and VKORC1 allele-specific PCR and detection
primers and assay-specific microarrays.9
Idaho Technology, Inc. platform. The CYP2C9 and
VKORC1 Genotyping Reagents [rapid melting curve
analysis] (Idaho Technology, Inc., Salt Lake City Utah)
simultaneously screens for 3 variants (CYP2C9 *2 and *3,
and VKORC1 c.–1639GA). Briefly, genomic DNA was
amplified and alleles were discriminated using rapid
melting curve analysis and simple probes.16 Genotypes
were assigned using derivative peak melting temperature
analysis.17,18
Osmetech eSensor platform. The Osmetech eSensor War-
farin Sensitivity (IUO, Osmetech Molecular Diagnostics,
Pasadena, CA) simultaneously screens for 10 variants
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(CYP2C9 *2, *3, *5, *6, *11, *14, *15, *16, VKORC1 c.–
1639 GA, and CYP4F2 c.1347 GA). Briefly, genomic
DNA was amplified and alleles were discriminated using
a DNA microarray with electrochemical detection of hy-
bridization in a microfluidic cartridge. Genotypes were
assigned using the proprietary software.9
Laboratory-developed test using the Applied Biosystems
SNapShot platform. This proprietary method for the de-
tection of five variants was done as described above for
CYP2D6.
Laboratory-developed test using the Luminex Eragen plat-
form. Genomic DNA was amplified and alleles were dis-
criminated using amplification primers and target-spe-
cific extension (TSE) probes (Eragen Biosciences,
Madison WI). Genotypes were detected on a Luminex
100 or 200 IS Systems (Austin TX) and assigned using the
Multicode-PLx Analysis Software (Eragen Biosciences,
Madison WI).19,20
Laboratory-developed test for Taqman platform. Speci-
mens were analyzed using the Applied Biosystems Taq-
man Drug Metabolism Genotyping Assays for the detec-
tion of eight variants as described above.
UGT1A1 Assays
AutoGenomics INFINITI platform. The AutoGenomics
INFINITI UGT1A1 Assay (AutoGenomics, Inc., Carlsbad,
CA) simultaneously screens for 3 variants. The procedure
was as described above for CYP2D6 using UGT1A1 al-
lele-specific PCR, detection primers, and assay-specific
microarrays.
Hologic, Inc. (formerly Third Wave Technologies) INVADER
platform. The FDA-cleared UGT Kit (Hologic, Inc. Molec-
ular Solutions, Bedford, MA) simultaneously screens for
three variants; other alleles are not reported by the soft-
ware. Invader probes hybridize to target DNA and a
capture probe to create a single base, triple DNA strand
structure that is cleaved to release an oligonucleotide
flap. This oligonucleotide is captured by a universal flu-
orescence resonance energy transfer (FRET) cassette
which is also cleaved at a single bp three-strand overlap
to release a fluorescent signal. Subsequent rounds of flap
oligo capture and FRET produces an amplified signal
detection of the initial Invader SNP detection. The fluo-
rescent signal is detected and genotypes are assigned
using proprietary software. (Hologic Invader UGT1A1
Molecular Assay, Bedford, MA).
Laboratory-developed test using PCR and capillary electro-
phoresis. This proprietary method for the detection of
three variants includes the amplification of genomic
DNA followed by size-fractionation using capillary
electrophoresis on an ABI3130xl and ABI3100 (Ap-
plied Biosystems, Inc., Foster City CA). Automated
allele calling is accomplished using ABI software (Gen-
emapper) and associated macros (Applied Biosys-
tems, Inc., Foster City, CA).
Protocol
Each of the testing laboratories received one 10-g ali-
quot of DNA from each of the cell lines to be tested. For
logistical reasons (related to cost of reagents, staffing,
and batched run size), the 107 DNA samples were di-
vided into three nonoverlapping sets: Set 1 (35 DNA
samples), Set 2 (36 DNA samples), and Set 3 (36 DNA
samples). Based on an individual laboratory’s resources
and testing platform, each laboratory tested one or more
sets of samples to ensure that each set was tested using
multiple platforms. The samples were coded, and the
expected genotypes were not revealed to the laborato-
ries. DNA sample set(s) were analyzed using the labora-
tories’ standard assay methods. The assay platforms
used in the study, the alleles detected by each, and the
sample set(s) tested with each method are indicated in
Table 1. The results were submitted to the study coor-
dinators (L.V.K. and V.M.P.), who examined the data
for quality and discrepancies. If discrepancies were
noted, the participating laboratory was requested to
re-evaluate the sample in question (without providing
the expected genotype) to determine whether there
were analytical or postanalytical (such as transcription)
errors. We did not perform direct DNA sequence anal-
ysis to resolve discrepancies because most of the
participating laboratories were not able to provide this
service.
Results
Each locus (CYP2D6, CYP2C19, CYP2C9, VKORC1,
and UGT1A1) was tested in three to six laboratories
using different assay platforms (Table 1). There were
no false negative and two false positive results (de-
scribed in detail below). The expected genotype (if
known from previous data from Coriell) of each DNA
sample was confirmed by all assay platforms designed
to detect the alleles, and there was good overall con-
cordance among laboratories. However, there were
some differences in allele assignments related to the
limitations of the manufacturer’s assay design and vari-
able nomenclature, especially for CYP2D6. The con-
sensus genotype for each DNA sample is shown in
Table 2. The alleles detected by each assay platform
varied, but most of the common variants were identified
among the set of 107 DNA samples. Table 3 lists the
alleles that were interrogated for each locus as well as
those that were identified or absent from the samples
screened.
CYP2D6
CYP2D6 was the most challenging of the loci tested in
this study. All of the assays used were designed to detect
the *2 through *7, *10 and *17 alleles. Each of the assays
detected various additional CYP2D6 alleles, with the
Roche Amplichip Assay detecting the largest number of
alleles. Of the 26 possible CYP2D6 alleles included in the
assays used in this study, fifteen (*2, *3, *4, *5, *6, *9, *10,
*17, *19, *29, *35, *41, *1XN, *2XN, and *4XN) were
identified among the 107 DNA samples. Laboratories did
not detect alleles *7, *11, *12, *14, *15, *19, *20, *36, *40,
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Table 2. Consensus Genotypes†
Set 1: Consensus genotype
Cell line number CYP2D6 CYP2C19 CYP2C9 VKORC1 c.-1639GA‡ UGT1A1
GM17227 *1/*9 *1/*1 *1/*2 GA *28/*28
GM12244 *35/*41 *1/*1 *2/*3 GG *1/*28
GM17240 *1/*10 *1/*1 (*1/*17) *1/*1 AA *1/*1
GM17289 *2/*4 *2/*2 *1/*1 AA *1/*1
GM17221 *1XN/*2 *1/*1 *2/*3 GA *1/*1
GM17119 *1/*2 *1/*1 (*1/*17) *1/*1 GG *1/*37
GM17129 *1/*4 *1/*1 *1/*2 GG *1/*36
GM17235 *1/*5 *1/*1 *1/*1 GG *1/*28
GM17203 *4/*35 *1/*2 (*2/*17) *1/*1 GA *1/*1
GM17058 *10/*10 *1/*2 *1/*1 AA *1/*28
GM17281 *5/*9 *1/*1 (*1/*17) *1/*1 GA *1/*28
GM17293 *2/*9 *1/*1 (*1/*17) *1/*2 GA *28/*28
GM17115 *1/*2 *1/*1 *1/*1 (*9/*9) GG *28/*28
GM17114 *1/*5 *1/*1 *1/*1 GG *1/*28
GM17084 *1/*10 *2/*4 *1/*2 GA *1/*1
GM17039 *2/*17 *1/*1 *1/*1 (*1/*9) GG *1/*36
GM17300 *1/*6 *1/*1 (*1/*17) *1/*1 GA *1/*28
GM17210 *1/*4 *1/*1 *1/*2 AA *1/*1
GM17247 *1/*2 *1/*1 *3/*3 GA *1/*28
GM10005 *17/*29 *1/*1 (*1/*17) *1/*1 (*1/*9) GG *1/*1
GM17057 *1/*10 *1/*1 *1/*1 GA *1/*1
GM17280 *2/*3 *1/*8 *1/*2 GG *1/*1
GM17252 *4/*5 *1/*1 *2/*3 GA *28/*28
GM17204 *1/*35 *1/*1 *1/*3 AA *1/*1
GM09301 Duplication *1/*1 (*1/*17) *1/*1 GG *28/*28
GM02016 *2XN/*17 *1/*2 *1/*1 GA *1/*1
GM17272 *4/*10 *1/*1 (*17/*17) *1/*1 AA *1/*28
GM17296 *1/*9 *1/*1 (*17/*17) *1/*1 GA *28/*28
GM17298 *1/*1XN *1/*1 *1/*1 GA *1/*28
GM17248 *4/*10 *1/*1 (*17/*17) *1/*1 AA *28/*28
GM12273 *1/*1 *1/*2 *1/*2 GG *1/*28
GM17246 *4/*35 *1/*8 (*8/*17) *1/*2 GA *1/*28
GM07439 *4XN/*41 *2/*2 (*2/*10) *1/*1 (*1/*9) GG *1/*28
GM17130 *1/*2 *1/*1 (*1/*17) *1/*3 GG *1/*37
GM17052 *1/*1 *1/*3 *1/*1 AA *1/*1
Set 2: Consensus genotype
Cell line number CYP2D6 CYP2C19 CYP2C9 VKORC1 c.-1639GA‡ UGT1A1
GM17215 *4/*41 *1/*1 *1/*3 GG *1/*1
GM16688 *2/*10 *2/*3 *1/*1 AA *1/*1
GM17245 *2/*4 *1/*2 *1/*2 GA *1/*28
GM17218 *2/*2 (*35) *1/*2 *1/*1 GG *1/*1
GM17438 *2/*4 *1/*1 *1/*2 AA *28/*37
GM17618 *1/*2 *1/*1 *1/*1 GA *1/*28
GM17213 *1/*2 (*35) *1/*1 (*1/*17) *1/*1 GA *1/*1
GM17285 *1/*1 *1/*1 *2/*3 AA *1/*1
GM17209 *1/*4 *1/*1 *1/*2 GG *1/*28
GM17216 *1/*1 *1/*1 *1/*2 AA *1/*28
GM17208 *2/*41 *1/*1 *1/*1 GA *28/*28
GM17237 *1/*4 *1/*2 (*2/*17) *1/*1 AA *1/*28
GM17232 *2/*2XN *1/*2 (*2/*17) *1/*1 GA *1/*1
GM17230 *4/*41 *1/*1 (*1/*17) *1/*1 GA *1/*1
GM17207 *2/*41 *1/*2 *1/*1 GG *28/*28
GM17260 *2/*2 *1/*2 (*2/*17) *1/*1 GA *1/*28
GM17242 *1/*1 *1/*1 *1/*1 GA *1/*28
GM17254 *4/*41 *1/*1 *2/*3 GG *1/*28
GM17256 *2 (*35)/*2 (*35) *1/*1 *1/*1 GA *1/*1
GM17201 *1/*1 *1/*2 *1/*1 GA *1/*28
GM16689 *2/*10 *2/*2 *1/*1 AA *1/*1
GM17205 *1/*41 *1/*2 *1/*2 GA *1/*1
GM17078 *1/*1 *1/*2 *1/*2 GG *1/*36
GM17440 *1/*1 *1/*1 *1/*1 GA *1/*28
GM17466 *1/*2 *1/*1 (*1/*17) *1/*1 GG *1/*1
GM17277 *1/*1 *1/*1 (*1/*17) *1/*1 AA *1/*28
(table continues)
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*10XN, *17XN, *35XN, and *41XN in any of the samples
tested.
Several discrepancies were identified in the CYP2D6
data (Table 4). We identified one false positive result for
GM17289. This assay was not repeated, so we were
unable to resolve the cause of the false positive result
(*29, Autogenomics), however, the results from the other
platforms agreed with one another, therefore this sample
was assigned the genotype *2/*4. Additionally, one plat-
form, the Roche Amplichip, was unable to genotype sev-
eral samples (GM17084, GM17252, GM17244, and
GM17287) due to limitations of the allele-calling algorithm
used for interpretation in this assay format (Table 4).
These “no calls” were likely due either to a combination of
detected alleles which was not recognized by the soft-
ware or to the presence of some rare alleles that were
detected by the AmpliChip CYP450 Test, but were not
reported because their phenotypes were not known.
Table 2. Continued
Set 2: Consensus genotype
Cell line number CYP2D6 CYP2C19 CYP2C9 VKORC1 c.-1639GA‡ UGT1A1
GM17020 *1/*10 *1/*1 *1/*1 AA *1/*1
GM17220 *1/*4 *1/*1 (*1/*17) *1/*1 GA *1/*28
GM17228 *1/*1 *1/*1 *1/*2 GG *1/*28
GM17224 *1/*1 *1/*2 *1/*1 GG *1/*1
GM17206 *2/*4 *1/*1 *1/*3 GG *1/*28
GM17211 *2/*4 *1/*1 *1/*3 GA *1/*1
GM17226 *4/*4 *1/*1 *1/*2 GA *28/*28
GM17219 *1/*1 *1/*2 *1/*1 GG *28/*28
GM17262 *2/*41 *1/*1 (*17/*17) *1/*1 GG *1/*1
GM17222 *1/*2 *1/*1 *2/*2 GA *28/*28
Set 3: Consensus genotype
Cell line number CYP2D6 CYP2C19 CYP2C9 VKORC1 c.-1639GA‡ UGT1A1
GM17214 *2/*2 *1/*2 *1/*1 GG *1/*1
GM17244 DUP/*4/*2A *1/*1 *1/*1 AA *1/*1
GM17217 *1/*41 *1/*1 *1/*1 GG *1/*28
GM17073 *1/*17 *1/*1 *1/*1 GG *28/*28
GM17282 *41/*41 *1/*1 *1/*1 GG *28/*28
GM17295 *1/*4 *1/*2 *1/*2 GA *1/*28
GM17233 *1/*41 *1/*1 *1/*1 GG *1/*1
GM17269 *2/*41 *1/*2 *1/*1 GA *1/*1
GM17264 *1/*4 *1/*2 (*2/*17) *1/*1 GG *1/*1
GM17265 *2/*2 *1/*1 *1/*1 AA *1/*28
GM17292 *4/*4 *1/*2 (*2/*17) *1/*1 GA *1/*28
GM17288 *1/*1 *1/*2 (*2/*17) *1/*1 GA *1/*28
GM17287 *1/*1 (*36/?) *1/*1 (*1/*17) *1/*1 GG *1/*28
GM17257 *2/*4 *1/*1 (*1/*17) *1/*1 GA *28/*28
GM17019 *1/*10 *1/*1 *1/*3 GA *1/*1
GM17290 *1/*41 *1/*2 *1/*3 GG *1/*1
GM17276 *2/*5 *1/*1 (*1/*17) *1/*1 GG *1/*28
GM17268 *1/*4 *1/*1 *1/*2 GG *1/*1
GM17291 *1/*4 *1/*1 *1/*3 GA *1/*28
GM17283 *4/*41 *1/*1 *1/*2 GG *1/*1
GM17243 *2 (*35)/*4 *1/*1 (*1/*17) *1/*2 AA *1/*1
GM17249 *1/*41 *1/*1 (*1/*17) *1/*2 GA *1/*1
GM17275 *1/*1 *1/*1 (*1/*17) *1/*1 GA *1/*28
GM17234 *1/*41 *1/*1 *1/*3 GG *1/*1
GM16654 *10/*10 *1/*2 *1/*1 GA *1/*1
GM17212 *1/*1 *1/*2 *1/*2 GG *1/*28
GM17229 *1/*2 *1/*1 *1/*1 AA *1/*28
GM17261 2 (*35)/*4 *1/*1 *1/*2 GA *1/*28
GM17286 *1/*4 *1/*1 *1/*1 GA *1/*28
GM17236 *2/*41 *1/*1 *1/*1 GG *1/*28
GM17267 *1/*4 *1/*1 *1/*1 GA *1/*1
GM17231 *1/*2 *1/*1 *1/*2 GG *1/*28
GM17075 *1/*2 *1/*1 *2/*2 GA *1/*28
GM17263 *1/*1 *2/*2 *1/*1 GA *1/*28
GM17274 *1/*2 *1/*1 (*1/*17) *1/*2 GA *1/*1
GM17279 *4/*41 *1/*1 (*17/*17) *1/*1 GG *1/*1
† Genotypes in parentheses were detected by assays performed in only one laboratory. The results were not verified because no other assays
designed to detect the allele were included in this study.
‡ VKORC1, only c.-1639GA (3673) is indicated. Data for other alleles are available on the GeT-RM Web site http://wwwn.cdc.gov/
dls/genetics/rmmaterials/default.aspx.
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When discrepant results among assays were identified,
the SNPs detected by each assay were examined to
determine the consensus *alleles in each sample, re-
ported in Table 2. There were also several CYP2D6 gene
duplications identified. Some of the platforms/assays do
not specify which allele is duplicated and in one sam-
ple (GM09301) a consensus genotype was not ob-
tained (Table 4).
The CYP2D6 *2B allele (c.1039CT, c.1661GC,
c.2850CT, c.4180GC) was recently reclassified as
*35 (c.-1584CG, c.31GA, c.1661GC, c.2850CT,
c.4180GC). However, functionally they are equivalent.
This change affected six samples (GM17218, GM17213,
GM17256, GM17287, GM17243, and GM17261). All six
were identified by the FDA-cleared Roche Amplichip with at
least one *35 allele. The two other platforms (AutoGenomics
INFINITI and Luminex xTag) do not discriminate the *35
allele (and genotyped these samples as CYP2D6 *2) and
therefore *35 could not be verified by these assays for these
samples (Table 4).
The CYP2D6 genotype of sample GM17287 was
designated a “No Call” by the Roche Amplichip (Table
4). On examination of the SNPs detected, the sample
was positive for *36, however the Roche assay was the
only one designed to detect *36 which is described as
a gene conversion in exon 9 (www.cypalleles.ki.se/
cyp2d6.htm, last accessed on June 14, 2010), thus a
CYP2D6 consensus genotype of *1/*1 was assigned
because the *36 was not confirmed by any of the other
assays.
Finally, the results for sample GM17119 were also
discrepant. On examination of the algorithms used by
each assay to determine allele status, this sample was
assigned a CYP2D6 consensus genotype of *1/*2
rather than *1/*41 (genotype obtained by Roche Am-
plichip), because it did not have the *41 defining
Table 3. Alleles Identified in the DNA Samples Tested
Locus
CYP2D6 CYP2C19 CYP2C9 VKORC1† UGT1A1
Alleles found in study
samples
*2, *3, *4, *5, *6,
*9, *10, *17, *19,
*29, *35, *41,
*1XN, *2XN, *4XN
*2, *3, *4, *8, *10,
*17





Alleles not found in study
samples
*7, *11, *12, *14,
*15, *19, *20, *36,
*40, *10XN, *17XN,
*35XN, *41XN
*5, *6, *7, *9,
*12
*4, *5, *6, *8,
*11, *12, *14, *15, *16
Alleles interrogated by
only one method
*19, *20, *36, *40,
*35XN






† VKORC1, only c.-1639GA (3673) is indicated. Data on the other alleles available on the GeT-RM Web site (http://wwwn.cdc.gov/dls/
genetics/rmmaterials/default.aspx.
Alleles not tested in sets 2 and 3 are underlined.











GM17289 *2/*4 *2/*4 *2/*4 *2 (*29)/*4,*10 *2A/*4 *2A/*4
GM17084 *1/*10 NC¶ *2/*10 *2/*10 *1/*10 *1/*10
GM17252 *4/*5 NC *4/*5 *4,*10/*5, *4/*5 *4/*5
GM17244 DUP/*4/*2A NC** NA¶ *2/*4,*10, XN DUP/*4/*2A NA
GM17287 *1/*1 (*36/?) NC†† NA *1/*1 *1/*1 NA
GM09301 Duplication *1/*41XN *2/*X2 (DUP) *2/XN DUP/*2 *1/*1XN
GM17218 *2/*2 (*35) *2/*35 NA *2/*2 *2A/*2A NA
GM17213 *1/*2 (*35) *1/*35 NA *1/*2 *1/*2A NA
GM17256 *2 (*35)/*2 (*35) *35/*35 NA *2/*2 *2A/*2A NA
GM17243 *2 (*35)/*4 *4/*35 NA *2/*4,*10 *2A/*4 NA
GM17261 *2 (*35)/*4 *4/*35 NA *2/*4,*10 *2A/*4 NA
GM17119 *1/*2 *1/*41 *1/*2 *1/*2 *1/*2 *1/*1
† Where no mutation is detected, *1 is assumed.
‡ Genotypes in parentheses were detected by assays performed in only one laboratory. The results were not verified because no other assays
designed to detect the allele were included in this study.
§ NA, not applicable, as platform was not used to test DNA from the cell line.
¶ NC, No call (*10; Haplotype: c.100CT, c.1039CT, c.1661GC, c.2850CT, c.4180GC).
 NC, No call [*4/*5; Haplotype: c.100CT(mut), c.1039CT, c.1661GC(mut), c.1846GA(mut), c.4180GC(mut); deletion detected].
** NC, No call [*2/*4 duplication identified; Haplotype: c.-1584CG, c.100CT, c.1661GG(mut), c.1846GA, c.2850CT, c.4180GC(mut);
duplication positive].
†† NC, No call (*36/?; Haplotype: *36 gene conversion, c.4180GC).
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c.2988GA SNP based on negative findings by Au-
toGenomics INFINTI, Luminex xTag and ParagonDx
assays that are designed to detect this specific SNP
(Tables 1 and 4).
CYP2C19
The CYP2C19 assays used in this study are designed to
detect a variety of CYP2C19 polymorphisms, including
the common nonfunctional (poor metabolizing) variants
*2 and *3. Several of the assays have the capacity to
detect the nonfunctional *4, *5, *6, *7, and *8 alleles, and
a few of these are also capable of detecting one or more
of the decreased function *9, *10, and *12 alleles as well
as the increased function *17 allele (Table 1) (Human
Cytochrome P450 [CYP] Allele Nomenclature Committee
http://www.cypalleles.ki.se/cyp2c19.htm, last accessed
on February 11, 2010). This study identified genomic
DNA samples containing *2, *3, *4, *8, *10 and *17 (Table
2). We did not detect several other CYP2C19 alleles
included in the assays used (Table 3). The Luminex
assay reported a *1/*2 genotype for sample GM07439.
This assay was not repeated by the laboratory to confirm
the result. The other platforms, however, reported that
this sample was either a *2/*2 or a *2/*10, so we assigned
it a *2/*2 (*2/*10) genotype. Only one of the assays used
is designed to detect the *10 allele, which shares SNPs
with the *2 allele, thus its presence in this sample has not
been confirmed.
CYP2C9, VKORC1
All seven laboratory tests identified the decreased function
alleles CYP2C9 *2, *3 (*1 was assumed when no mutations
were detected), and VKORC1 c.1639 (3673) GA among
the 107 DNA samples of the study set (Table 2). These are
the most common variant alleles observed in the white
population, which is the ethnicity represented by 75% of
samples in the study. In addition, one of the assays de-
tected CYP2C9 *9, an allele specific to blacks.21 Only one
laboratory tested for this variant and reported that three cell
lines were heterozygous for the *9 allele and one was ho-
mozygous for this variant. Currently this finding has not
been confirmed using any other methods. Additional
CYP2C9 alleles were included in some of the assays but
were not detected among the 107 samples, although sam-
ple sets 2 and 3 were not screened with methods that
detected other variant alleles (Tables 1 and 3). The Auto-
Genomics platform is designed to detect VKORC1 c.1639
(3673) GA as well as seven other VKORC1 alleles that are
not included in the other assays. All of the alleles included in
this platform were identified in one or more of the 107
samples tested (Table 3, data available on the GeT-RM
websitehttp://www.cdc.gov/dls/genetics/rmmaterials/default.
aspx, last accessed on September 16, 2010). There was
complete concordance among laboratories for each of the
CYP2C9 and VKORC1 variant alleles within the detection
capacities of the test methods used.
UGT1A1
All of the UGT1A1 assay platforms used in this study were
designed to detect three UGT1A1 variant alleles (*28, *36
and *37; *1 was assumed if no variant allele is detected).
We were able to identify each of these alleles in one or
more of the107 DNA samples (Table 3). There was com-
plete concordance among laboratories for each of the
UGT1A1 variant alleles within the detection capacities of
the test methods used.
Other Loci
A subset of laboratories also reported results for 15 other
pharmacogenetic (CYP4F2, EPHX1, ABCB1, HLAB, KIF6,
CYP3A4, CYP3A5, TPMT, DPD) and nonpharmacoge-
netic loci (F5, F2, HFE,MTHFR, AAT, PAI1) (data available
on the GeT-RM website http://www.cdc.gov/dls/genetics/
rmmaterials/default.aspx, last accessed on September 16,
2010). Each of these additional loci was characterized by
one or two laboratories depending on the assays avail-
able in the laboratory and the capacity to assay the
samples.
Discussion
This study describes the characterization of 107 publicly
available cell line–derived genomic DNA samples for five
pharmacogenetic loci, CYP2D6, CYP2C9, VKORC1,
CYP2C19, and UGT1A1 that are commonly included in
clinical pharmacogenetic testing. Each sample was
tested in multiple laboratories using a variety of assay
platforms, although there are a number of other platforms
that were not included in this study. This strategy ensures
that the DNA would be thoroughly characterized and will
be commutable among a variety of assay platforms. We
were able to identify many, but not all, of the alleles
commonly included in clinical assays for the five loci. The
GeT-RM program will further this work with the pharma-
cogenetic testing community and the Coriell Cell Repos-
itories to identify cell lines with these missing alleles and
undertake the necessary characterization studies. In ad-
dition to the five loci characterized by multiple laborato-
ries, this study also generated genotypic information for
an additional fifteen pharmacogenetic and nonpharma-
cogenetic loci. These data will be useful to laboratories
developing and validating new genetic tests. The
GeT-RM will use the initial genotypic results from these
additional 15 loci as a starting point for future reference
material characterization projects. This may include
genotyping DNA from additional cell lines to identify sam-
ples that encompass all of the alleles in available plat-
forms. Also the 107 cell lines’ DNA may be characterized
for additional PGx markers or the initial genotype results
may be confirmed using a multilaboratory study.
Currently there are a number of commercially available
platforms as well as LDTs used for clinical testing of PGx
loci. With the exception of a few commercially available cell
lines and synthetic DNA products, some of which are FDA-
cleared and some of which are Research or Investigational
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Use Only, characterized genomic DNA RMs are not avail-
able for PGx testing. International, federal, and state regu-
lations and professional guidelines require the inclusion of
reference or quality control materials during the analysis of
patient samples22–26 (European Molecular Genetics Quality
Network, http://emqn.org/eqmn/bestpractice.html, last ac-
cessed on August 4, 2009; Washington State Legislature,
http://apps.leg.wa.gov/WAC/default.aspx?cite_246–338,
last accessed on August 4, 2009; New York State
Clinical Laboratory Evaluation Program, http://www.
wadsworth.org/labcert/clep/clep.html, last accessed on
August 4, 2009; College of American Pathologists, http://
www.cap.org, last accessed on August 4, 2009; Ameri-
can College of Medical Genetics, http://www.acmg.net/
Pages/ACMG_Activities/stds-2002/g.htm, last accessed
on August 4, 2009). Reference materials are also used for
development of new genetic tests including those for
PGx, test validation, and other quality assurance
purposes.23
In the absence of available characterized reference
materials, laboratories often use unconfirmed and non-
renewable sources of genomic DNA such as residual
patient specimens. This approach, while feasible, is
not optimal because samples with uncommon alleles
are often difficult to obtain and the supply of these
materials is limited. In addition, the residual samples
used as reference materials should be characterized
using a method other than the one used to test them
initially, or by an independent laboratory.27 The public
availability of a renewable source of genomic DNA
reference materials that have been characterized us-
ing a variety of methods, such as the 107 genomic DNA
reference materials characterized in this study, will
also facilitate assay standardization among laborato-
ries. It should be noted that the purified genomic DNA
materials characterized in this study serve only as
positive controls for analysis of PGx polymorphisms. It
does not control for the entire testing process, includ-
ing DNA extraction from whole blood.
The Human Cytochrome P450 (CYP) Allele Nomencla-
ture Committee website (http://www.cypalleles.ki.se/ , last
accessed on January 7, 2010) indicates the defining
sequence variants for the major *alleles of each of the
CYP genes. Allele nomenclature may change over time
and is updated as more information becomes available
regarding the functional SNPs and enzymatic activity of
each allele. The SNPs used to define each of the
CYP2C9, CYP2C19, VKORC1, and UGT1A1 *alleles were
consistent among the assays used in this study (Table 5).
However, the SNPs which define the CYP2D6 *alleles
were highly variable between assays. Some assays/plat-
forms only detect the major SNP that defines each of the
CYP2D6 *alleles (AutoGenomics INFINITI, ParagonDX,
and a LDT in our study), whereas other assays/platforms
detect multiple SNPs for each CYP2D6 *allele (Luminex
xMap and Roche Amplichip).
Variability in allele definition between various assay plat-
forms can create discrepant results and reporting. There
are two examples of this within the CYP2D6 data set: *4
versus *10 and *2 versus *41 (Table 4). CYP2D6 *4 and *10
enzymes, have no and decreased activity, respectively. The
major SNP in *4 is c.1846GA, which causes a splicing
defect that abrogates enzymatic activity, but other SNPs in
the *4 haplotype may include the following: c.100CT,
c.974CA, c.984AG, c.4180GC. In *10, the major de-
fining SNP is c.100CT, which causes a proline to serine
change associated with decreased enzymatic activity. Both
*4 and *10 alleles include c.100CT and c.4180GC,
which is also contained in *2 and other CYP2D6 alleles,
indicating that many of the variant alleles likely arose on the
same haplotype background (Table 5) (Human Cyto-
chrome P450 [CYP] Allele Nomenclature Committee http://
www.cypalleles.ki.se/cyp2d6.htm, last accessed on Febru-
ary 11, 2010). Presence of c.100CT and c.1846GA is
consistent with a *4 allele, but the Autogenomics assay
reports both *10 and *4 for this SNP combination. The
potential exists that a *1/*4 patient could be misidentified as
*4/*10 due to the inability to assign the correct allele based
on the combination of SNPs present. This could affect clin-
ical management of drug therapy because *4/*10 (nonfunc-
tional allele/decreased functional allele) and *1/*4 (normal
functional allele/nonfunctional allele) have a different pre-
dicted phenotype. In the Roche package insert, *1/*4 is
assigned an extensive metabolizer phenotype, while *4/*10
is assigned an intermediate metabolizer phenotype. How
laboratory directors using SNP-only platforms are assigning
genotypes and metabolizer status is not part of this project
but remains a potential concern in clinical testing. Addition-
ally, assigning phase to the various SNPs is not addressed
by this study but may have implications in result interpreta-
tion and thus deserves further review.
The other major discrepancy in CYP2D6 genotyping
was differentiating *2 from *41. The *2 allele is defined
by c.2850CT and c.4180GC and is associated with
normal enzymatic function. The defining SNP in *41 is
c.2988GA, which is associated with decreased en-
zymatic activity due to altered RNA splicing.28,29 The
*41 haplotype also includes c.2850CT, c.4180GC,
and c.-1584C, which are also reported in some subsets
of *2. The Roche Amplichip does not include the de-
fining *41 SNP c.2988GA and thus may misclassify
some *2 alleles (*2L and *2M) as *41. This confusion
arose because it was unclear from initial studies which
single *41 SNP was responsible for decreased enzy-
matic function. Once studies showed an association
between c.2988GA and decreased enzymatic activ-
ity, alleles with c.-1584C but not c.2988GA were
reclassified as subsets of *2 (normal enzymatic activ-
ity). This affected results for sample GM17119, which
varied among platforms (Table 4).
In addition, there were other changes in allele nomen-
clature that had an impact on the consensus genotypes
reported for DNAs characterized in this study. The Hu-
man Cytochrome P450 (CYP) Allele Nomenclature Com-
mittee reclassified *2B as *35 (c.-1584CG, c.31GA,
c.1661GC, c.2850CT, c.4180GC), and the SNPs
c.1039CT, c.1661GC, c.2850CT, c.4180GC to
define *2B. This nomenclature change does not have
phenotype interpretation consequences, because both
are functional alleles. In our study, this change impacted
six samples (GM17218, GM17213, GM17256, GM17287,
GM17243, and GM17261) (Table 4). All six of these DNA
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samples were identified by the FDA-approved Roche
Amplichip as having at least one *35 allele. The two other
platforms (AutoGenomics INFINITI and Luminex xTag)
are not designed to identify the *35 allele because they
do not detect c.31GA; thus this genotype could not
be confirmed. Luminex xTag detects only *2A, while the
AutoGenomics INFINITI system does not indicate which
*2 subtype it detects. Changes to allele assignments are
made as more information is available; however, new
information resulting in nomenclature changes can im-
pact both manufacturers and laboratory scientists devel-
oping clinical assays and adds confusion to interpreta-
tion of clinical results.
In conclusion, we have characterized a set of 107
genomic DNA RMs for five pharmacogenetic loci
(CYP2D6, CYP2C19, CYP2C9, VKORC1, and UGT1A1),
using a variety of assay platforms in multiple pharma-
cogenetic testing laboratories. These samples can be
used for quality assurance, proficiency testing, and test
development and research and should help ensure the
accuracy of pharmacogenetic testing. These pharma-
cogenetic RMs, as well as other materials developed
by GeT-RM, are publicly available from the NIGMS
repository at the Coriell Cell Repositories (http://ccr.
coriell.org/Sections/Collections/NIGMS/?SsId8, last
accessed on April 13, 2010). More information on this
and other reference material characterization projects
is available at the GeT-RM website: http://www.cdc.
gov/dls/genetics/rmmaterials/default.aspx, last ac-
cessed on September 16, 2010.
Table 5. Defining SNPs for Major Alleles of CYP2D6, CYP2C9, VKORC1, CYP2C19, and UGT1A1
SNP Allele† dbSNP rs#
CYP2D6*2 c.2850CT, c.4180GC rs16947,
CYP2D6*3 c.2549delA rs4986774
CYP2D6*4 c.100CT, c.1846GA, c.4180GC rs3892097
CYP2D6*5 Whole gene deletion
CYP2D6*6 c.1707delT rs5030655
CYP2D6*7 c.2935AC
CYP2D6*8 c.1758GT, c.2850CT, c.4180GC
CYP2D6*9 c.2615_2617delAAG rs28371720
CYP2D6*10 c.100CT, c.4180GC rs1065852
CYP2D6*11 c. 883GC, c. 2850CT, c.4180GC
CYP2D6*12 c.124GA, c.2850CT, c.4180GC
CYP2D6*14 c.1758GA, c.2850CT, c.4180GC
CYP2D6*15 c.138insT
CYP2D6*17 c.1023CT, c.2850CT, c.4180GC rs28371706
CYP2D6*19 c.2539–2542delAACT, c.2850CT, c.4180GC
CYP2D6*20 c.1973insG, c.2850CT, c.4180GC
CYP2D6*29 c.2850CT, c.3183GA, c.4180GC
CYP2D6*35 c.31GA, c.2850CT, c.4180GC
CYP2D6*36 c.100CT, c.4180GC, gene conversion in exon 9
CYP2D6*40 c.1023CT, c.1863ins(TTTCGCCCC)2, c.2850CT, c.4180GC

























UGT1A1*28 A (TA)7TAA rs81753476
UGT1A1*36 A (TA)5TAA rs81753476
UGT1A1*37 A (TA)8TAA rs81753476
† Defining SNP in bold.
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